Oncotarget Is Helping Scientists Gain Impact in Oncology and Pathology

Oncotarget is a medical journal published by Impact Journals. It was started in 2010, and the editors are Andrei V. Gudkov and Mikhail Blagosklonny, of Roswell Park Cancer Institute.

Oncotarget helps their authors maximize their impact and the impact of their medical searches. This is one reason why it’s so popular and is growing in popularity. Gordon Research Conference is one sponsor of Oncotarget. A Nobel Prize Winner, Andrew Schally, and the former Editor in Chief of Cancer Research, Carlo M. Croce, have published many articles in Oncotarget. Andrew Schally published 27 papers in Oncotarget, and Carlo M. Croce published 10 papers. This shows us an insight into some of the authors at Oncotarget. Indeed, there are many esteemed and highly respected medical professionals who publish papers in Oncotarget on a regular basis. Oncotarget is also available on Dove Press.

Although Oncology is the main focus of Oncotarget, they cover other related medical fields as well, such as Cardiology, Metabolism, Neuroscience, Endocrinology, Cell Biology, all areas of Pharmacology, and many other related medical fields. On Reuters’ Impact Factor, it showed that Oncotarget reached over ten thousand cities over the last year or two, which is an incredible deal.

Oncotarget also is ranked as number one in all medical journals that are related to Oncology. There is free access to Oncotarget, and they publish new free articles and issues online every single week. Their ultimate goal is to have life without disease. Of course, research plays in important role in such a goal, and that is why Oncotarget is focused on helping scientists publish their research and help gain impact for them.

For an example of other medical issues they cover, there is pathology. It was launched under the leadership of Michael Lisanti, who is the former editor in chief of the American Journal of Pathology, and the pathology section has an impact score of 6.63 for two straight years in a row, which is amazing.

Compared to other stand alone pathology journals, the pathology section of Oncotarget has a much higher impact score, gets published faster and more often, and within two days of acceptance, your paper can appear online and in other formats.

Check more http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget

Mikhail Blagosklonny’s Contribution In Cancer And Aging Research

Mikhail Blagosklonny is a cancer and aging scientist. He works at Roswell Park Cancer Institute, Buffalo, New York as an oncology professor. Mikhail is an alumnus of the First Pavlov State Medical University of St. Petersburg where he earned his M.D in internal medicine and a PhD in experimental medicine and cardiology.

According to Impact Journals, Mikhail Blagosklonny joined New York Medical College in 2002 as an associate professor of medicine and later took up a role of senior scientist at Ordway Research Institute Albany, NY. He worked here until 2009 when he joined Roswell Park Cancer Institute.

Research Gate reveals that Mikhail Blagosklonny has researched on a wide range of topics in the field including molecular and cellular biology and clinical investigations, narrowing down to oncogenes and tumor suppressors, cell cycle, signal transduction, apoptosis, mitosis, resistance of drugs for selective protection of normal cells and anticancer therapeutics focusing on basic science in new anticancer strategies.

Under this aging research, Mikhail Blagosklonny formulated a hypothesis to study the possible role of TOR signaling in cancer and aging.

The clinical significance of this research showed that suppressed TOR activity extends life span in S. cerevisiae, D. melanogaster and C. elegans. Rapamycin, which inhibits mTOR was found to increase mice’s lifespan. Studies have indicated that some dietary regimes like methionine restriction and caloric restriction decreases mTOR activity, resulting into lifespan extension.

There have also been suggestions that aging may increase mTOR signaling in certain tissues like the adipose tissue. In cancer, mTOR activity was revealed to be deregulated in most types of cancer while over-activation of mTOR signaling enhances the development of tumors.

Mikhail Blagosklonny is the founder and editor-in-chief of Cell Cycle, Aging and Oncotarget. He is an active member of the editorial board of Cell Death & Differentiation.

He is also an associate editor for Cancer Biology & Therapy. Mikhail works for Autophagy, The American Journal of Pathology, PLOS ONE and Cancer Research as an associate editor.